Scholarlink

<p>Conventional targeted therapies primarily rely on small molecules and proteins. However, they often struggle to enter specific protein conformations, which limits their therapeutic effectiveness. In contrast, RNA therapy is emerging as a more precise and effective targeting strategy. Through differential analysis comparing Pandora-Seq data with clinical samples, we discovered that the small RNA <i>piR-28846</i> naturally, occurring in human body, exhibited low expression levels in ovarian cancer tissues. Experimental results indicate that <i>piR-28846</i> inhibits the growth of ovarian cancer cells. Additionally, <i>piR-28846</i> demonstrated significant therapeutic effects in xenograft models and ovarian cancer-like organoids. Further studies revealed that <i>piR-28846</i> binds to NSUN2 and down-regulates it, which in turn affects the stability of KPNA2 mRNA. Notably, KPNA2 negatively regulates NSUN2 expression and localization. Given its inhibitory effects observed in vivo, in vitro, and in the ovarian cancer organoid model, we believe <i>piR-28846</i> has strong potential as a small nucleic acid therapy of ovarian cancer.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

piRNA28846 has the potential to be a novel RNA nucleic acid drug for ovarian cancer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年3月8日

查看全文
  • Hong-lei Qin,
  • Yang Han,
  • Jian-qi Li,
  • Qing-hua Wu,
  • Yu-ping Du,
  • Qian-hui Li,
  • Xi Chen,
  • Yong-peng Wang,
  • Xue Guan,
  • Xiu-jie Sheng,
  • Shuo Chen,
  • Yang Zhao

摘要

Conventional targeted therapies primarily rely on small molecules and proteins. However, they often struggle to enter specific protein conformations, which limits their therapeutic effectiveness. In contrast, RNA therapy is emerging as a more precise and effective targeting strategy. Through differential analysis comparing Pandora-Seq data with clinical samples, we discovered that the small RNA piR-28846 naturally, occurring in human body, exhibited low expression levels in ovarian cancer tissues. Experimental results indicate that piR-28846 inhibits the growth of ovarian cancer cells. Additionally, piR-28846 demonstrated significant therapeutic effects in xenograft models and ovarian cancer-like organoids. Further studies revealed that piR-28846 binds to NSUN2 and down-regulates it, which in turn affects the stability of KPNA2 mRNA. Notably, KPNA2 negatively regulates NSUN2 expression and localization. Given its inhibitory effects observed in vivo, in vitro, and in the ovarian cancer organoid model, we believe piR-28846 has strong potential as a small nucleic acid therapy of ovarian cancer.